The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Masters, S. L., Dunne, A., Subramanian, S. L., Hull, R. L., Tannahill, G. M., Sharp, F. A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., et al. (2010) · Nature Immunology · doi:10.1038/ni.1935 · Cited by 1,330
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Upregulated NLRP3 Inflammasome Activation in Patients With Type 2 Diabetes
Lee, H.-M., Kim, J.-J., Kim, H. J., Shong, M., Ku, B. J., & Jo, E.-K. (2013) · Diabetes · doi:10.2337/db12-0420 · Cited by 734
Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes
Shah, M. S., & Brownlee, M. (2016) · Circulation Research · doi:10.1161/circresaha.116.306923 · Cited by 602
NLRP3 inflammasomes link inflammation and metabolic disease
De Nardo, D., & Latz, E. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.05.004 · Cited by 425
NLRP3 Gene Silencing Ameliorates Diabetic Cardiomyopathy in a Type 2 Diabetes Rat Model
Luo, B., Li, B., Wang, W., Liu, X., Xia, Y., Zhang, C., Zhang, M., Zhang, Y., & An, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104771 · Cited by 408
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., Espadero, R.-M., Woerle, H.-J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 399
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 391
The Inflammasomes in Kidney Disease
Anders, H.-J., & Muruve, D. A. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080798 · Cited by 351
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 310
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Abdul-Ghani, M., Del Prato, S., Chilton, R., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dc16-0041 · Cited by 295
Vrhovac, I., Balen Eror, D., Klessen, D., Burger, C., Breljak, D., Kraus, O., Radović, N., Jadrijević, S., Aleksic, I., Walles, T., et al. (2015) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-014-1619-7 · Cited by 290
Kasichayanula, S., Liu, X., LaCreta, F., Griffen, S. C., & Boulton, D. W. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0104-3 · Cited by 276
Udell, J. A., Cavender, M. A., Bhatt, D. L., Chatterjee, S., Farkouh, M. E., & Scirica, B. M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00044-3 · Cited by 254
Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes
Daniele, G., Xiong, J., Solis-Herrera, C., Merovci, A., Eldor, R., Tripathy, D., DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2016) · Diabetes Care · doi:10.2337/dc15-2688 · Cited by 213
Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)
Zhou, L., Cryan, E. V., D'Andrea, M. R., Belkowski, S., Conway, B. R., & Demarest, K. T. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10631 · Cited by 206
Obermeier, M., Yao, M., Khanna, A., Koplowitz, B., Zhu, M., Li, W., Komoroski, B., Kasichayanula, S., Discenza, L., Washburn, W., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029165 · Cited by 183
Bae, H. R., Kim, D. H., Park, M. H., Lee, B., Kim, M. J., Lee, E. K., Chung, K. W., Kim, S. M., Im, D. S., & Chung, H. Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12119 · Cited by 181
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury
Chang, Y.-K., Choi, H., Jeong, J. Y., Na, K.-R., Lee, K. W., Lim, B. J., & Choi, D. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158810 · Cited by 176
De Nicola, L., Gabbai, F. B., Liberti, M. E., Sagliocca, A., Conte, G., & Minutolo, R. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.02.010 · Cited by 167
Luo, B., Li, B., Wang, W., Liu, X., Liu, X., Xia, Y., Zhang, C., Zhang, Y., Zhang, M., & An, F. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6498-1 · Cited by 150
Kornelius, E., Lin, C., Chang, H., Li, H., Huang, W., Yang, Y., Lu, Y., Peng, C., & Huang, C. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12404 · Cited by 137
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2014) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12223 · Cited by 132
Kashiwagi, Y., Nagoshi, T., Yoshino, T., Tanaka, T. D., Ito, K., Harada, T., Takahashi, H., Ikegami, M., Anzawa, R., & Yoshimura, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130605 · Cited by 117
Dai, Y., Dai, D., Wang, X., Ding, Z., & Mehta, J. L. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6539-4 · Cited by 116
Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-014-0324-3 · Cited by 114
Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
Benetti, E., Mastrocola, R., Vitarelli, G., Cutrìn, J. C., Nigro, D., Chiazza, F., Mayoux, E., Collino, M., & Fantozzi, R. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235069 · Cited by 104
Fuentes‐Antrás, J., Ioan, A.-M., Tuñón, J., Egido, J., & Lorenzo, Ó. (2014) · International Journal of Endocrinology · doi:10.1155/2014/847827 · Cited by 103
Effects of DPP-4 inhibition on cardiac metabolism and function in mice
Lenski, M., Kazakov, A., Marx, N., Böhm, M., & Laufs, U. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.08.001 · Cited by 88
Birnbaum, Y., Bajaj, M., Qian, J., & Ye, Y. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000227 · Cited by 87
Self-citationNlrp3 Inflammasome Activation in Type 2 Diabetes: Is It Clinically Relevant?
Dixit, V. D. (2013) · Diabetes · doi:10.2337/db12-1115 · Cited by 85
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
Narendran, P., & Saeed, M. A. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s50963 · Cited by 71
Effect of dapagliflozin on colon cancer cell [Rapid Communication]
Saito, T., Okada, S., Yamada, E., Shimoda, Y., Osaki, A., Tagaya, Y., Shibusawa, R., Okada, J., & Yamada, M. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0396 · Cited by 66
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.05.006 · Cited by 64
Murase, H., Kuno, A., Miki, T., Tanno, M., Yano, T., Kouzu, H., Ishikawa, S., Tobisawa, T., Ogasawara, M., Nishizawa, K., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0264-6 · Cited by 59
Ghosh, R. K., Bandyopadhyay, D., Hajra, A., Biswas, M., & Gupta, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.134 · Cited by 53
Anders, H., & Lech, M. (2013) · Kidney International · doi:10.1038/ki.2013.122 · Cited by 51
Saxagliptin Restores Vascular Mitochondrial Exercise Response in the Goto-Kakizaki Rat
Keller, A. C., Knaub, L. A., Miller, M. W., Birdsey, N., Klemm, D. J., & Reusch, J. E. B. (2014) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000170 · Cited by 50
Tirmenstein, M. A., Dorr, T. E., Janovitz, E. B., Hagan, D. L., Abell, L. M., Onorato, J. M., Whaley, J. M., Graziano, M. J., & Reilly, T. P. (2013) · International Journal of Toxicology · doi:10.1177/1091581813505331 · Cited by 38
Inflammation and immunity in diabetic vascular complications
Nilsson, J. Å., Bengtsson, E., Fredrikson, G. N., & Björkbacka, H. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32830f47cd · Cited by 36
MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis inob/obmice
Ohyama, T., Sato, K., Yamazaki, Y., Hashizume, H., Horiguchi, N., Kakizaki, S., Mori, M., Kusano, M., & Yamada, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i43.16227 · Cited by 31
The NLRP3 Inflammasome and Diabetic Cardiomyopathy
Singh, L. P. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6501-x · Cited by 26
Millar, P., Pathak, V., Moffett, R. C., Pathak, N., Bjourson, A. J., O’Kane, M., Flatt, P. R., & Gault, V. A. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.11.019 · Cited by 24
Combination therapy with saxagliptin and dapagliflozin for the treatment of type 2 diabetes
Williams, D. M., & Stephens, J. W. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1088830 · Cited by 23
Cited by
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Mouton, A. J., Li, X., Hall, M. E., & Hall, J. E. (2020) · Circulation Research · doi:10.1161/circresaha.119.312321 · Cited by 546
Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy
Yang, F., Qin, Y., Wang, Y., Meng, S., Xian, H., Che, H., Lv, J., Li, Y., Yu, Y., Bai, Y., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.29680 · Cited by 461
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Ketone bodies: from enemy to friend and guardian angel
Kolb, H., Kempf, K., Röhling, M., Lenzen-Schulte, M., Schloot, N. C., & Martin, S. (2021) · BMC Medicine · doi:10.1186/s12916-021-02185-0 · Cited by 361
Metadata
- Authors
- Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y.
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 2017-04
- Volume
- 31
- Issue
- 2
- Pages
- 119-132
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W2608233061
- Cited by
- 368
- References
- 48
- FWCI
- 17.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.